Ali Rizvi to Risk Factors
This is a "connection" page, showing publications Ali Rizvi has written about Risk Factors.
Connection Strength
0.403
-
Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther. 2015; 15(10):1391-7.
Score: 0.063
-
Vitamin D deficiency in patients with congestive heart failure: mechanisms, manifestations, and management. South Med J. 2011 May; 104(5):325-30.
Score: 0.047
-
Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci. 2009 Oct; 338(4):310-8.
Score: 0.042
-
The role of inflammation in diabetes and its complications. South Med J. 2006 Jan; 99(1):8-9.
Score: 0.032
-
Recognition and implications of the metabolic syndrome. J S C Med Assoc. 2004 Apr; 100(4):107-12.
Score: 0.029
-
Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochim Biophys Acta Mol Basis Dis. 2021 08 01; 1867(8):166148.
Score: 0.023
-
Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Res Clin Pract. 2019 Mar; 149:163-169.
Score: 0.020
-
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016 Dec 03; 15(1):162.
Score: 0.017
-
Incretins, Pregnancy, and Gestational Diabetes. Curr Pharm Biotechnol. 2016; 17(7):597-602.
Score: 0.016
-
Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. Clin Cardiol. 2014 Sep; 37(9):517-22.
Score: 0.015
-
Diabetic ketoalkalosis in children and adults. South Med J. 2014 Jan; 107(1):6-10.
Score: 0.014
-
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2013 Sep; 6(9):914-22.
Score: 0.014
-
Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr Pharm Des. 2013; 19(21):3858-68.
Score: 0.013
-
Prevalence and impact of initial misclassification of pediatric type 1 diabetes mellitus. South Med J. 2012 Oct; 105(10):513-7.
Score: 0.013
-
Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention. 2012 May 15; 8(1):87-93.
Score: 0.013
-
The role of elevated growth hormone on the increased atherosclerosis in patients with acromegaly. Angiology. 2012 Oct; 63(7):492-4.
Score: 0.012
-
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009 Oct; 18(10):1495-503.
Score: 0.010
-
The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance? Acta Diabetol. 2009 Mar; 46(1):1-11.
Score: 0.010